Passage Bio Reports Financial Results for Q3 2025
Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company, recently disclosed their financial outcomes for the third quarter ended September 30, 2025. Among the highlights, the company noted advances in their ongoing upliFT-D clinical trial, which aims to tackle frontotemporal dementia (FTD) with promising therapeutic options.
Key Clinical Developments
One of the most significant updates involves the active enrollment of Cohort 3 (FTD-GRN) and Cohort 4 (FTD-C9orf72) patients within the upliFT-D study, which utilizes PBFT02. This trial aims to evaluate the safety and efficacy of the treatment regimen. Dr. Will Chou, CEO of Passage Bio, expressed enthusiasm regarding the trial's progress, indicating a commitment to expanding therapy options for individuals diagnosed with neurodegenerative conditions.
Collaboration with the FDA
The company has successfully aligned with the U.S. Food and Drug Administration (FDA) regarding an analytical approach to ensure the comparability of their PBFT02 manufacturing process. This engagement marks a crucial step in preparing for future registrational studies, highlighting Passage Bio's proactive measures in regulatory compliance.
Expectations for 2026
Looking ahead, Passage Bio anticipates obtaining valuable regulatory feedback concerning the FTD-GRN registrational trial design by the first half of 2026. This feedback is crucial for shaping the study and advancing their treatment methods further.
Recent Financial Highlights
Passage Bio's cash position remains resilient, with cash equivalents and marketable securities totaling $52.8 million as of the quarter's end. This amount is expected to support company operations well into early 2027, reflecting prudent financial management amid operational advancements.
Operating Expenses Overview
The company reported research and development expenses of $4.3 million for the third quarter of 2025, which is significantly lower than the previous year's $8.7 million. General and administrative expenses followed a similar trend, decreasing to $4.3 million from $7.3 million year-over-year. This decrease illustrates Passage Bio's stringent cost management strategies while focusing on clinical development.
Net Loss Analysis
The net loss for the latest quarter was recorded at $7.7 million, translating to a loss of $2.44 per basic and diluted share. This represents a marked improvement compared to a net loss of $19.3 million for the same period the previous year. This reduction signals positive momentum in transitioning toward a more sustainable financial future.
About PBFT02 and the upliFT-D Study
PBFT02 is essential to Passage Bio's therapeutic strategy, targeting the underlying causes of frontotemporal dementia. The study evaluates patient safety and tolerability, with secondary focuses on biomarkers and clinical outcomes. With strong patient enrollment initiatives, Passage Bio collaborates with partners to enhance genetic counseling and increase trial participation.
Future Prospects and Milestones
Anticipated milestones include the reporting of interim safety and biomarker data in the first half of 2026 and further regulatory discussions regarding the FTD-GRN study design. These steps represent critical components in their ongoing journey towards developing effective treatments for neurodegenerative diseases.
Frequently Asked Questions
What financial results did Passage Bio report for Q3 2025?
Passage Bio reported a net loss of $7.7 million for Q3 2025, showing a notable improvement over the previous year.
What is PBFT02?
PBFT02 is a treatment being investigated by Passage Bio for its potential to address neurodegenerative diseases, particularly frontotemporal dementia.
How much cash does Passage Bio currently have?
As of September 30, 2025, Passage Bio has $52.8 million in cash, cash equivalents, and marketable securities.
What is the upliFT-D study?
The upliFT-D study is a Phase 1/2 clinical trial for PBFT02 targeting patients with FTD- GRN and FTD- C9orf72.
What is the company's outlook for 2026?
Passage Bio expects to gain regulatory feedback on their clinical trial design for the FTD-GRN program in the first half of 2026, with additional data releases anticipated.
